ASCO 2022

Promising Depth of Response Data in Renal Cell Carcinoma: Insights from CheckMate 9ER Trial - Cristina Suárez

Advanced Prostate Cancer Practice Informing Data Presented at ASCO 2022 - Neeraj Agarwal

Optimizing Multi-Disciplinary Care Teams for Radiopharmaceutical Administration - Neal Shore

Durvalumab Alone or with Savolitinib or Tremelimumab in Previously Treated Advanced Clear Cell Renal Cancer - CALYPSO Trial Results - Tom Powles

PSMA PET Imaging in Clinical Practice - Thomas Hope & Jeremie Calais

The Effect of Metastasis-Directed Therapy (MDT) on Oligometastatic Castration-Sensitive Prostate Cancer Outcomes - Philip Sutera

The ORACLE Study: The Efficacy of Combination Systemic Therapies in Patients with Non-Clear Cell Renal Cell Carcinoma - Deepak Kilari

Long-Term Outcomes in EV-301, Enfortumab Vedotin Versus Chemotherapy in Patients With Previously Treated Advanced Urothelial Carcinoma - Jonathan Rosenberg

The Intensified Treatment Landscape of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) - Russell Szmulewitz

PROCLAIM Study Reveals Impact of Germline Genetic Testing on Prostate Cancer Clinical Decisions - Neal Shore

Progression Patterns by Types of Metastatic Spread, PSA, and Clinical Symptoms - Post-Hoc Analyses of ARAMIS - Alicia Morgans

The Promising Path of PSMA PET Imaging and Lutetium-177-PSMA in GU Oncology and Prostate Cancer Treatment - Susan Slovin

PSMA PET Scan Imaging in Prostate Cancer - Ashley Ross

CAR T and Cellular-Based Therapies - Vivek Narayan

Results of a Phase II Randomized Double Blind Trial of PF-04518600, OX40 Antibody, in Combination with Axitinib - Sarmad Sadeghi

A Novel Imaging Modality, FAP Imaging for Patients with Bladder Cancer - Vadim S. Koshkin

A Pre-Specified Gene-by-Gene Analysis of Primary and Secondary Endpoints in the MAGNITUDE Clinical Trial - Shahneen Sandhu

Multidisciplinary Care for Patients, a Book Interview - Alicia Morgans

Multidisciplinary Care Teams to Optimize Care of Patients with Bone Metastatic CRPC - Tanya Dorff

Imaging and PET Analysis as a Prognostic Tool for Lu-PSMA-617 Treatment in Patients with mCRPC - Phillip H. Kuo

Biomarker-Directed Therapy in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Clara Hwang

Clinical Trial Endpoints in the Adjuvant Setting for Renal Cell Carcinoma and Urothelial Cancer - Andrea Apolo and Pavlos Msaouel

The Future of Radiopharmaceuticals in the Treatment of Prostate Cancer - Philip Kantoff

Timing and Intensity of ADT in Biochemical Recurrence - Channing J. Paller

CheckMate 214: A Deep Dive into Ipilimumab and Nivolumab for Advanced Renal Cell Carcinoma - David Cella

Immunotherapy and PARP Inhibitors in Biochemical Recurrent Prostate Cancer - Alexandra Sokolova

How Does the Data from the PEACE-1, ARASENS and ENZAMET Studies Inform Clinical Practice? - Karim Fizazi

BRCAAway - a Randomized Phase 2 Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with mCRPC with DNA Repair Defects - Maha Hussain

The Efficacy and Safety of Relugolix versus Leuprolide in the HERO Study in Men with Advanced Prostate Cancer Based on Baseline BMI - Fred Saad

Optimizing the Use of Radium-223 Through Multidisciplinary Collaboration - Phillip Koo

Overall Survival Outcomes in ENZAMET (ANZUP 1304), Trial of Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer - Ian Davis

The Association of PSA Response and Overall Survival in Patients with mHSPC in the Phase 3 ARASENS Trial - Fred Saad

Long-Term Outcomes from JAVELIN Bladder 100 - Cora Sternberg

No Longer ADT Alone in Metastatic Hormone-Sensitive Prostate Cancer, The ARASENS Trial - Cora Sternberg

Theranostics in Prostate Cancer Management - The TheraP Trial - Michael Hofman

ATLANTIS Trial Explores Precision Medicine in Urothelial Carcinoma - Robert Jones

Fast Facts: The Importance of Genetic Testing in Prostate Cancer - Brittany Szymaniak

Patient-Centric Approaches: The Urgent Need for Genetic Testing in Prostate Cancer - Brittany Szymaniak

Advancing Genetic Testing in Metastatic Prostate Cancer - Brenda Martone

Treatment with Radium-223 and Effects on Bone Health in Patients with mCRPC - Fred Saad

Identifying the Right Patients for Treatment with Radium-223 for mCRPC - Brenda Martone